Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.63 |
| ▸ | TK2 | O00142 | 2/20 | 0.58 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Netivudine SCHEMBL18052692 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL6153401 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL112727 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL112726 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL9538356 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL1585773 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL462884 | 0.97 | PYGM (0.60) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL22028728 | 0.92 | P2RY6 (0.57) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL21276349 | 0.91 | PYGM (0.51) | PYGMTK2DNPH1P2RY2TSHR | |
| SCHEMBL1060638 | 0.90 | PYGM (0.51) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1060182-B1 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2012-12-19 | — | — | EP | claimed |
| US-8080536-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | claimed |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2011-01-13 | — | — | US | claimed |
| US-7816345-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2010-10-19 | — | — | US | claimed |
| US-20080125605-A1 | Novel Phosphorus-Containing Prodrugs | METABASIS THERAPEUTICS, INC. | 2008-05-29 | — | — | US | claimed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| EP-1165570-B9 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1724276-A1 | Novel phosphorus-containing prodrugs | Metabasis Therapeutics, Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| EP-1165570-B1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | claimed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | claimed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | claimed |
| EP-1060182-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | Metabasis Therapeutics, Inc. (US) | 2000-12-20 | — | — | EP | claimed |
| WO-1999045016-A9 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999045016-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS, INC. (US) | 1999-09-10 | — | — | WO | claimed |
| EP-0542952-A1 | USE OF 1-(-g(b)-D-ARABINOFURANOSYL)-5-PROPYNYLURACIL FOR LOWERING SERUM CHOLESTEROL. | WELLCOME FOUND (GB) | 1993-05-26 | — | — | EP | claimed |
| WO-1992021352-A1 | USE OF 1-(β-D-ARABINOFURANOSYL)-5-PROPYNYLURACIL FOR LOWERING SERUM CHOLESTEROL | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-12-10 | — | — | WO | claimed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20180214464-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | CHIMERIX, INC. | 2018-08-02 | — | — | US | disclosed |
| EP-0486477-A2 | 1-( -D-Arabinofuranosyl)-5-propynyluracil as a VZV-antiviral compound | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-20 | — | — | EP | disclosed |
| EP-0346108-A2 | Anti-infective nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125605-A1 | Novel Phosphorus-Containing Prodrugs | PYGL, ALPI, SLC10A1 | PYGM 100/4885TK2 470/4885SLC28A1 77/4885 |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | PYGM 582/4885TK2 540/4885SLC28A1 1605/4885 |
| US-20180214464-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | TPMT, HAVCR2, REV1 | PYGM 2788/4885TK2 482/4885SLC28A1 134/4885 |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | PYGM 100/4885TK2 470/4885SLC28A1 77/4885 |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | PYGM 977/4885TK2 747/4885SLC28A1 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.